Research & Development

Verastem Oncology announces new strategic direction to advance its clinical development programmes

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, announced a new strategic direction to accelerate the advancement of certain of its clinical development programmes.

Boehringer Ingelheim enters discovery stage collaboration with Trutino Biosciences

Boehringer Ingelheim and Trutino Biosciences today announced they have entered into a research collaboration and worldwide licensing agreement based on Trutino’s innovative On-Demand-Cytokine (ODC) platform.

Japan’s Takeda buys PvP Biologics in $330m deal

Japan Takeda Pharmaceutical has exercised its option to acquire PvP Biologics in a deal valued at around $330m.

Novartis, DNDi to jointly develop LXE408 for visceral leishmaniasis

Novartis has signed a collaboration and licence agreement with the Drugs for Neglected Diseases initiative (DNDi) for the joint development of LXE408 as a new oral drug for the treatment of visceral leishmaniasis.

Genentech, Bicycle Therapeutics sign immuno-oncology therapies deal

Roche Group’s member Genentech has signed a novel immuno-oncology therapies deal with biotechnology firm Bicycle Therapeutics.

GSK, Clover collaborate to assess protein-based coronavirus vaccine candidate

British drugmaker GlaxoSmithKline (GSK) has collaborated with Chinese firm Clover Biopharmaceuticals to assess coronavirus (COVID-19) vaccine candidate with the pandemic adjuvant system.

Genetron Health, InnoCare collaborate to accelerate development and commercialisation of novel drugs for cancer treatment

Genetron Holding, a China-based precision oncology company that covers full-cycle cancer care, has announced a strategic partnership with Beijing InnoCare Pharma to provide clinical trial genomic testing and companion diagnostics development services for InnoCare’s biomarker-driven oncology drug development.

GSK signs cancer therapies deal with Immatics Biotechnologies

British drugmaker GlaxoSmithKline (GSK) has entered into a deal with Immatics Biotechnologies for the development of novel adoptive cell therapies for multiple cancer indications.

Humanetics acquires manufacturing assets for radioprotectant drug

Humanetics announced that it has entered into a definitive agreement with DSM Nutritional Products Ltd of Kaiseraugst Switzerland to acquire all of DSM’s assets related to the manufacture of the active pharmaceutical ingredient (API) in BIO 300, a clinical stage drug being developed by Humanetics for oncology and biodefense applications.